Indication
Complement component 3 glomerulopathy
Complement component 3 glomerulopathy (C3G) is a rare, complement-mediated renal disorder affecting the glomeruli across pediatric and adult populations. Read more about Complement component 3 glomerulopathy
3 drugs 3 manufacturers
Drugs that treat it
Common Complement component 3 glomerulopathy therapies.
FABHALTA (iptacopan HCl)
FABHALTA (iptacopan HCl)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonComplement component 3 glomerulopathy (C3G) is a rare, complement-mediated renal disorder affecting the glomeruli across pediatric and adult populations.
It is caused by acquired or genetic dysregulation of the alternative complement pathway, resulting in excessive complement activation in the circulation and within the glomerular microenvironment.
Pathophysiologically, the disease is defined on renal biopsy by prominent, dominant deposition of complement component 3 (C3) with absent or minimal immunoglobulin staining, comprising two major histological subtypes: C3 glomerulonephritis and dense deposit disease.
Clinically, affected patients typically present with hematuria, proteinuria, nephritic or nephrotic syndrome, and progressive decline in kidney function that frequently advances to end-stage renal disease.
- nih.gov
Complement component 3 glomerulopathy (C3G) is a rare, complement-mediated renal disorder affecting the glomeruli across pediatric and adult populations It is caused by acquired or genetic dysregulation of the alternative complement pathway, resulting in excessive complement activation in the circulation and within the glomerular microenvironment Pathophysiologically, the disease is defined on renal biopsy by prominent, dominant deposition of complement component 3 (C3) with absent or minimal im...
- nih.gov
It is caused by acquired or genetic dysregulation of the alternative complement pathway, resulting in excessive complement activation in the circulation and within the glomerular microenvironment Clinically, affected patients typically present with hematuria, proteinuria, nephritic or nephrotic syndrome, and progressive decline in kidney function that frequently advances to end-stage renal disease
- nih.gov
Pathophysiologically, the disease is defined on renal biopsy by prominent, dominant deposition of complement component 3 (C3) with absent or minimal immunoglobulin staining, comprising two major histological subtypes: C3 glomerulonephritis and dense deposit disease
Personalize your experience
Follow Complement component 3 glomerulopathy and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.